Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
- DOI
- 10.1093/ehjcvp/pvac028
- Published
- 2022 Dec 2
- Container
- European heart journal. Cardiovascular pharmacotherapy
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ehjcvp/pvac028,
title = {Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.},
author = {Fox KAA and Aboyans V and Debus ES and Zeymer U and Cowie MR and Patel M and Welsh RC and Bosch J and Gay A and Vogtländer K and Anand SS},
year = {2022},
journal = {European heart journal. Cardiovascular pharmacotherapy},
doi = {10.1093/ehjcvp/pvac028},
url = {https://doi.org/10.1093/ehjcvp/pvac028}
}RIS
TY - JOUR TI - Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. AU - Fox KAA AU - Aboyans V AU - Debus ES AU - Zeymer U AU - Cowie MR AU - Patel M AU - Welsh RC AU - Bosch J AU - Gay A AU - Vogtländer K AU - Anand SS PY - 2022 JO - European heart journal. Cardiovascular pharmacotherapy DO - 10.1093/ehjcvp/pvac028 UR - https://doi.org/10.1093/ehjcvp/pvac028 ER -
APA
KAA, F., V, A., ES, D., U, Z., MR, C., M, P., RC, W., J, B., A, G., K, V., & SS, A. (2022). Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.. European heart journal. Cardiovascular pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvac028
Source records
- pubmed · retrieved 2026-09-26T00:36:23.358Z
- europe-pmc · retrieved 2026-09-26T00:36:23.367Z
- hal · retrieved 2026-09-26T00:36:23.414Z